Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis : Safety and effectiveness data from the German Hepatitis C-Registry
© 2021 The Authors. Liver International published by John Wiley & Sons Ltd..
Glecaprevir/pibrentasvir, a pangenotypic, direct-acting antiviral combination approved for chronic hepatitis C virus treatment, has limited real-world evidence supporting 8-week therapy in compensated cirrhosis. We investigated effectiveness and safety of 187 hepatitis C virus-infected, treatment-naïve, patients with compensated cirrhosis receiving 8-week glecaprevir/pibrentasvir therapy in the German Hepatitis C-Registry between 2 August 2017 and 1 January 2020. Sustained virologic response was 98.4% (127/129) in the per-protocol analysis (excluding patients lost to follow-up or who discontinued treatment due to compliance) and was 85.8% (127/148) in patients with data available in an intention-to-treat analysis. Nineteen patients were lost to follow-up; nine genotype 3 patients, nine nongenotype 3 patients and one mixed genotype patient. One patient relapsed, and one died, unrelated to treatment. Adverse events (>5%) were fatigue and headache. Two serious adverse events occurred; no adverse events resulted in drug discontinuation. An 8-week glecaprevir/pibrentasvir therapy was effective and well-tolerated in this real-world analysis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Liver international : official journal of the International Association for the Study of the Liver - 41(2021), 7 vom: 09. Juli, Seite 1518-1522 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Klinker, Hartwig [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.06.2021 Date Revised 04.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/liv.14937 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325180180 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325180180 | ||
| 003 | DE-627 | ||
| 005 | 20231225191905.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/liv.14937 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1083.xml |
| 035 | |a (DE-627)NLM325180180 | ||
| 035 | |a (NLM)33966349 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Klinker, Hartwig |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis |b Safety and effectiveness data from the German Hepatitis C-Registry |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.06.2021 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The Authors. Liver International published by John Wiley & Sons Ltd. | ||
| 520 | |a Glecaprevir/pibrentasvir, a pangenotypic, direct-acting antiviral combination approved for chronic hepatitis C virus treatment, has limited real-world evidence supporting 8-week therapy in compensated cirrhosis. We investigated effectiveness and safety of 187 hepatitis C virus-infected, treatment-naïve, patients with compensated cirrhosis receiving 8-week glecaprevir/pibrentasvir therapy in the German Hepatitis C-Registry between 2 August 2017 and 1 January 2020. Sustained virologic response was 98.4% (127/129) in the per-protocol analysis (excluding patients lost to follow-up or who discontinued treatment due to compliance) and was 85.8% (127/148) in patients with data available in an intention-to-treat analysis. Nineteen patients were lost to follow-up; nine genotype 3 patients, nine nongenotype 3 patients and one mixed genotype patient. One patient relapsed, and one died, unrelated to treatment. Adverse events (>5%) were fatigue and headache. Two serious adverse events occurred; no adverse events resulted in drug discontinuation. An 8-week glecaprevir/pibrentasvir therapy was effective and well-tolerated in this real-world analysis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a 8 weeks | |
| 650 | 4 | |a cirrhosis | |
| 650 | 4 | |a glecaprevir | |
| 650 | 4 | |a hepatitis C virus | |
| 650 | 4 | |a pibrentasvir | |
| 650 | 7 | |a Aminoisobutyric Acids |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Benzimidazoles |2 NLM | |
| 650 | 7 | |a Cyclopropanes |2 NLM | |
| 650 | 7 | |a Lactams, Macrocyclic |2 NLM | |
| 650 | 7 | |a Pyrrolidines |2 NLM | |
| 650 | 7 | |a Quinoxalines |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 650 | 7 | |a pibrentasvir |2 NLM | |
| 650 | 7 | |a 2WU922TK3L |2 NLM | |
| 650 | 7 | |a Proline |2 NLM | |
| 650 | 7 | |a 9DLQ4CIU6V |2 NLM | |
| 650 | 7 | |a Leucine |2 NLM | |
| 650 | 7 | |a GMW67QNF9C |2 NLM | |
| 650 | 7 | |a glecaprevir |2 NLM | |
| 650 | 7 | |a K6BUU8J72P |2 NLM | |
| 700 | 1 | |a Naumann, Uwe |e verfasserin |4 aut | |
| 700 | 1 | |a Rössle, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Berg, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Bondin, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Lohmann, Kristina |e verfasserin |4 aut | |
| 700 | 1 | |a Koenig, Bettina |e verfasserin |4 aut | |
| 700 | 1 | |a Zeuzem, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Cornberg, Markus |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Liver international : official journal of the International Association for the Study of the Liver |d 2003 |g 41(2021), 7 vom: 09. Juli, Seite 1518-1522 |w (DE-627)NLM124147356 |x 1478-3231 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2021 |g number:7 |g day:09 |g month:07 |g pages:1518-1522 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/liv.14937 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2021 |e 7 |b 09 |c 07 |h 1518-1522 | ||